Marksans Pharma Q1FY27: Record Profitability, Cash Crosses ₹1,000 Cr; EBITDA Up 113%
Marksans Pharma reported record Q1FY27 results with EBITDA at ₹213 crore (up 113% YoY) and PAT at ₹159 crore (up 174% YoY). Operating revenue grew 35.6% to ₹841 crore. Cash balance crossed ₹1,000 crore, reaching ₹1,058 crore. UK & Europe revenue hit a record ₹356 crore, up 74.7%.
The announcement details record financial performance, including substantial growth in profitability and revenue, a significant increase in cash balance, and positive outlook from rating agencies. These are material factors that are likely to impact investor perception and the company's stock price.
The company reported record-breaking financial metrics including significant year-on-year growth in revenue, EBITDA, and PAT. The expansion in key markets like UK & Europe and a strong cash position further contribute to a positive sentiment.
Marksans Pharma Limited has announced its un-audited financial results for the quarter ended June 30, 2026, reporting record profitability and a cash balance exceeding ₹1,000 crore for the first time. The company's EBITDA surged by 113% year-on-year to ₹213 crore, while Profit After Tax (PAT) grew by 174% to ₹159 crore.
Operating revenue for the quarter stood at ₹841 crore, a 35.6% increase year-on-year. Gross profit rose by 38.9% to ₹497 crore, with a gross margin of 59.1%. The EBITDA margin improved significantly to 25.3%, and the net margin stood at 18.4%.
The UK & Europe region delivered its highest-ever quarterly revenue of ₹356 crore, marking a 74.7% year-on-year growth. This growth was bolstered by the acquisition of QliniQ, which contributed ₹44 crore in Q1FY27 and is seen as a significant step in the company's European expansion. The US & North America market contributed ₹377 crore, up 15.1% year-on-year, and Australia and New Zealand reported revenues of ₹88 crore, up 53.7% year-on-year.
Despite recent acquisitions, the company's cash balance reached ₹1,058 crore as of June 30, 2026. Cash generated from operations was ₹185 crore, and free cash flow was ₹152 crore. The working capital cycle improved to approximately 132 days from 159 days in the previous year. Research and development spending was ₹23 crore, representing 2.8% of consolidated revenue.
Mark Saldanha, Managing Director, expressed optimism, stating, "Q1FY27 has been a strong start to the year, with an all-time high quarterly EBITDA of ₹213 crore and PAT of ₹159 crore, reflecting the strength of our underlying business and our continued focus on profitable growth." He further highlighted the strategic importance of Europe and the company's strong balance sheet, positioning Marksans for sustainable growth. India Ratings and Research revised the outlook on the company's bank loan facilities to Positive from Stable.
What to do with a filing like this
Marksans Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Marksans Pharma Limited. Read the original for the full detail.